TriTACs are novel T cell-engaging therapeutic proteins optimized for the treatment of solid tumors and for long serum half-life

被引：3
|
作者：
Wesche, Holger [1 ]
Aaron, Wade [1 ]
Austin, Richard J. [1 ]
Baeuerle, Patrick A. [2 ]
Jones, Adrie [1 ]
Lemon, Bryan [1 ]
Sexton, Kenneth [1 ]
机构：
[1] Harpoon Therapeut, San Francisco, CA USA
[2] MPM Capital, Cambridge, MA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3814
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3814
引用
收藏
页数：2
相关论文
共 50 条
  • [1] TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid Tumors
    Austin, Richard J.
    Lemon, Bryan D.
    Aaron, Wade H.
    Barath, Manasi
    Culp, Patricia A.
    DuBridge, Robert B.
    Evnin, Luke B.
    Jones, Adrie
    Panchal, Anand
    Patnaik, Purbasa
    Ramakrishnan, Vanitha
    Rocha, Sony S.
    Seto, Pui
    Sexton, Kenneth
    Strobel, Kathryn L.
    Wall, Russell
    Yu, Stephen
    Yu, Timothy Z.
    Law, Che-Leung
    Baeuerle, Patrick A.
    Wesche, Holger
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (01) : 109 - 120
  • [2] A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
    Yoon, Aerin
    Lee, Shinai
    Lee, Sua
    Lim, Sojung
    Park, Yong-Yea
    Song, Eunjung
    Kim, Dong-Sik
    Kim, Kisu
    Lim, Yangmi
    BIOMOLECULES, 2020, 10 (03)
  • [3] ZW171, a T cell-engaging, bispecific antibody for the treatment of mesothelin-expressing solid tumors
    Afacan, Nicole J.
    Piscitelli, Chayne
    Zwierzchowski, Patricia
    Cao, Siran
    Li, Janessa
    Wong, Wingkie
    White-Moyes, Kara
    von Kreudenstein, Thomas Spreter
    Weisser, Nina E.
    CANCER RESEARCH, 2023, 83 (07)
  • [4] Engineered human FcγRIIa fusion: A novel strategy to extend serum half-life of therapeutic proteins
    Jo, Migyeong
    Ko, Sanghwan
    Hwang, Bora
    Min, Sung-Won
    Ha, Ji Yeon
    Lee, Ji Chul
    Jang, Se-Eun
    Jung, Sang Taek
    BIOTECHNOLOGY AND BIOENGINEERING, 2020, 117 (08) : 2351 - 2361
  • [5] HPN536, a T cell-engaging, mesothelin/CD3-specific TriTAC for the treatment of solid tumors
    Austin, Richard
    Aaron, Wade
    Baeuerle, Patrick
    Barath, Manasi
    Jones, Adrie
    Jones, Susan D.
    Law, Che-Leung
    Kwant, Kathryn
    Lemon, Bryan
    Muchnik, Anna
    Sexton, Kenneth
    Tatalick, Laurie
    Wesche, Holger
    Yu, Timothy
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors
    Yuan, Yuan
    Li, Junyan
    Chen, Jie
    Han, Lei
    Wang, Lei
    Yue, Yali
    Liu, Junjun
    Zhang, Baohong
    Yuan, Yunsheng
    Wu, Mingyuan
    Bian, Yanlin
    Xie, Yueqing
    Zhu, Jianwei
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174
  • [7] High-yield expression of Therapeutic proteins with extended serum half-life in tobacco cells
    Xu, Jianfeng
    Kieliszewski, Marcia J.
    JOURNAL OF BIOTECHNOLOGY, 2008, 136 : S169 - S169
  • [8] A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors
    Zhang, Wei
    Auguste, Aurelie
    Liao, Xiaoyun
    Walterskirchen, Christian
    Bauer, Kathrin
    Lin, Yu-Hsi
    Yang, Ling
    Sayedian, Farzaneh
    Fabits, Markus
    Bergmann, Michael
    Binder, Carina
    Corrales, Leticia
    Vogt, Anne B.
    Hudson, Lindsey J.
    Barnes, Martin P.
    Bisht, Arnima
    Giragossian, Craig
    Voynov, Vladimir
    Adam, Paul J.
    Hipp, Susanne
    CLINICAL CANCER RESEARCH, 2022, 28 (23) : 5190 - 5201
  • [9] A NOVEL HUMANIZED T CELL-ENGAGING CD24XCD3 BISPECIFIC ANTIBODY FOR CD24-POSITIVE SOLID TUMORS
    Espinosa-Cotton, Madelyn
    Guo, Hong-fen
    Cheung, Nai-Kong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1379 - A1379
  • [10] Site-specific fatty acid-conjugation of therapeutic proteins for the extended serum half-life
    Cho, Jinhwan
    Kwon, Inchan
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
12345